The polycythemia vera treatment landscape is evolving as patent expirations, high drug costs, and new therapies reshape the market. JAKAFI (ruxolitinib) has long been the leading option for patients resistant or intolerant to hydroxyurea. However, generic competition may not appear as soon as expected, potentially delaying cost relief for patients and healthcare systems.

The persistent question why is JAKAFI so expensive remains a concern, as annual treatment costs can surpass USD 100,000 depending on dosing and insurance coverage. While financial assistance programs exist, the high cost continues to challenge both patients and payers. Delayed generics mean this burden is unlikely to ease in the near term.

Competition is rising with the emergence of Besremi (ropeginterferon alfa-2b). Inclusion in the NCCN guidelines has increased physician confidence, and adoption rates are growing. Besremi offers a disease-modifying approach as a long-acting interferon, targeting the underlying clonal proliferation of abnormal blood cells rather than merely managing symptoms.

Pricing for Besremi is generally more cost-efficient over the long term compared to JAKAFI, though it varies by region. Patients and healthcare providers frequently discuss besremi side effects, including flu-like symptoms, fatigue, and mild liver enzyme elevations. Most side effects are manageable with dose adjustments, allowing patients to continue therapy long-term. Its twice-monthly dosing schedule also promotes adherence.

Another promising therapy is rusfertide, an injectable hepcidin mimetic from Protagonist Therapeutics. The drug aims to reduce the need for phlebotomy, a major quality-of-life concern for many patients. Although rusfertide FDA approval is pending, clinical trials show encouraging results in maintaining hematocrit levels and potentially lowering disease complications.

Rusfertide’s unique mechanism distinguishes it from JAK inhibitors and interferons, positioning it as a potential premium therapy. Regulatory challenges, such as the earlier withdrawal of Breakthrough Therapy Designation, slowed development but did not reduce enthusiasm. Many experts predict that rusfertide could reshape the polycythemia vera interferon therapeutics market once approved, offering patients a new therapeutic strategy.

Overall, 2025 is defined by delayed generic entry, rising competition, and pricing pressures. While JAKAFI (ruxolitinib) continues to lead the market, Besremi (ropeginterferon alfa-2b) and rusfertide are expanding the therapeutic landscape. The balance between affordability, clinical effectiveness, and patient choice will define the market in the coming years. Patients can look forward to more treatment options, but cost considerations will remain a key factor in care decisions.

Latest Reports Offered By DelveInsight:

Calciphylaxis Market | Carcinoid Tumor Market | Cardiac Arrhythmia Market | Cardiac Insufficiency Market | Cardiac Output Monitor Market | Chronic Pain Market | Dilated Cardiomyopathy Market | Erectile Dysfunction Market | Female Infertility Market | Foot and Ankle Devices Market | Gout Market | Hearing Implants Market | Infusion Pumps Market | Interspinous Spacers Market | Knee Osteoarthritis Market | Knee Reconstruction Devices Market | Metastatic Uveal Melanoma Market | Myeloproliferative Neoplasms Market | Myopia Progression Market Share | Nephroblastoma Market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us 

Kanishk

kkumar@delveinsight.com